Gene signatures for prediction of therapy-related myelodysplasia and methods for identification of patients at risk for development of the same
US9347102B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 7, 2013 |
| Grant date | May 24, 2016 |
| Priority date | — |
| Expiry date | Jun 7, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.